Amplyx’s first-in-class antifungal heads for a head-to-head study

Positive Phase II data set up fosmanogepix for pivotal trial to treat invasive Candida infections

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections.

Echinocandins are standard of care in the indication, but resistance to the class is a growing concern.

Fosmanogepix inhibits

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE